CVAid Medical
AI-based Stroke Disease Management Platform
Company Overview
Snapshot
Founded in October 2018 by Danny Farin, Oren Dror, Rotem Sivan-Hoffmann, and Nadav Eichler, CVAid Medical operates with 1–10 employees. The company has raised $4 million across two funding rounds from four investors.
Business overview
CVAid Medical specializes in stroke telemedicine, developing an AI-based platform for stroke diagnosis and disease management. The company's CVA-Flow system provides early and accurate stroke diagnosis using standard smartphones and cloud servers, supported by its CVA-Core artificial intelligence module. This comprehensive solution synchronizes all stakeholders, including patients, EMS, ER, and medical teams, by analyzing visual and auditory recordings of stroke patients with machine and deep learning tools to offer real-time support for neurologists in remote patient diagnosis. CVAid Medical operates within the Health Tech & Life Sciences sector, specifically in Digital Healthcare, Digital Medical Diagnostics, and Medical Decision Support, serving patients and providers globally.
Strategic signal
This investment highlights continued investor confidence in the company's AI-based stroke telemedicine platform, CVA-Flow. The participation of both venture capital and corporate venture arms suggests strategic validation of CVAid Medical's technology and its potential to improve stroke diagnosis and management, signaling a positive trajectory for market adoption and technological advancement.
Log in to access full profile ›Company Intelligence Q&A
- What is CVAid Medical's primary focus?
- CVAid Medical focuses on stroke telemedicine, aiming to improve stroke diagnosis and management through its AI-based platform, CVA-Flow.
- When was CVAid Medical founded?
- CVAid Medical was founded in October 2018.
- Who are the founders of CVAid Medical?
- The co-founders of CVAid Medical are Danny Farin, Oren Dror, Rotem Sivan-Hoffmann, and Nadav Eichler.
- What is CVAid Medical's core product?
- CVAid Medical's core product is CVA-Flow, a comprehensive telestroke system supported by its artificial-intelligence module, CVA-Core, designed for early and accurate stroke diagnosis and disease management.
- Which investors participated in CVAid Medical's February 2022 funding round?
- In February 2022, CVAid Medical received funding from RAD BioMed, Phillips Ventures, and Sanara Capital.